Nicotinic Acid Compositions For Treating Hyperlipidemia and Related Methods Therefor
Abstract
An orally administered antihyperlipidemia composition according to the present invention includes from about 250 to about 3000 parts by weight of nicotinic acid, and from about 5 to about 50 parts by weight of hydroxypropyl methylcellulose. Also, a method of treating hyperlipidemia in a hyper lipidemic having a substantially periodic physiological loss of consciousness, includes the steps of forming a composition having an effective antihyperlipidemic amount of nicotinic acid and a time release sustaining amount of a swelling agent. The method also includes the step of orally administering the composition to the hyperlipidemic once per day “nocturnally,” that is in the evening or at night.
Claims
exact text as granted — not AI-modified1 . (canceled)
2 . (canceled)
3 . (canceled)
4 . (canceled)
5 . (canceled)
6 . (canceled)
7 . (canceled)
8 . (canceled)
9 . (canceled)
10 . (canceled)
11 . (canceled)
12 . (canceled)
13 . A method for treating hyperlipidemia in a hyperlipidemic, the method comprising the step of:
dosing the hyperlipidemic with a sustained release oral solid dosage form comprising about 500 mg nicotinic acid once per day and wherein the antihyperlipidemic's total cholesterol, LDL cholesterol, triglycerides and Lp(a) are reduced and the antihyperlipidemic's HDL cholesterol is increased.
14 . The method according to claim 13 , wherein the hyperlipidemic is dosed at night or in the evening.
15 . A method for treating hyperlipidemia in a hyperlipidemic, the method comprising the step of:
dosing the hyperlipidemic with a sustained release oral solid dosage form comprising about 750 mg nicotinic acid once per day and wherein the antihyperlipidemic's total cholesterol, LDL cholesterol, triglycerides and Lp(a) are reduced and the antihyperlipidemic's HDL cholesterol is increased.
16 . The method according to claim 15 , wherein the hyperlipidemic is dosed at night or in the evening.
17 . A method for treating hyperlipidemia in a hyperlipidemic, the method comprising the step of:
dosing the hyperlipidemic with a sustained release oral solid dosage form comprising about 1000 mg nicotinic acid once per day and wherein the antihyperlipidemic's total cholesterol, LDL cholesterol, triglycerides and Lp(a) are reduced and the antihyperlipidemic's HDL cholesterol is increased.
18 . The method according to claim 17 , wherein the hyperlipidemic is dosed at night or in the evening.
19 . A method for treating hyperlipidemia in a hyperlipidemic, the method comprising the step of:
dosing the hyperlipidemic with a sustained release oral solid dosage form comprising about 2000 mg nicotinic acid once per day and wherein the antihyperlipidemic's total cholesterol, LDL cholesterol, triglycerides and Lp(a) are reduced and the antihyperlipidemic's HDL cholesterol is increased.
20 . The method according to claim 19 , wherein the hyperlipidemic is dosed at night or in the evening.
21 . The method according to claims 13 or 14 , wherein the sustained release oral solid dosage form is administered to the hyperlipidemic with food.
22 . The method according to claims 15 or 16 , wherein the sustained release oral solid dosage form is administered to the hyperlipidemic with food.
23 . The method according to claims 17 or 18 , wherein the sustained release oral solid dosage form is administered to the hyperlipidemic with food.
24 . The method according to claims 19 or 20 , wherein the sustained release oral solid dosage form is administered to the hyperlipidemic with food.Join the waitlist — get patent alerts
Track US2007225342A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.